13F Holdings
中文EN

BMRA BIOMERICA INC

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 73290 · Fiscal year ends 05/31

Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-11.2%
TTM net income YoY-37.0%
TTM EPS YoY-9.2%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—

Margins

Gross margin0.9%
Operating margin-125.2%
Net margin-115.5%
FCF margin—
EBITDA margin-123.6%

Returns

ROE-113.8%
ROA-67.1%
ROIC (approx.)-284.4%
Asset turnover0.58x

Leverage & solvency

Liabilities / assets54.8%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-05-31FY20252025-05-31FY20242024-05-31FY20232023-05-31FY20222022-05-31
Income statement
Revenue$4.45M$5.31M$5.42M$5.34M$18.87M
Cost of revenue$4.09M$4.81M$4.80M$4.89M$15.89M
Gross profit$362,000$498,000$611,000$446,000$2.98M
R&D expense$788,000$1.02M$1.49M$1.58M$1.81M
SG&A expense$4.89M$4.61M$5.49M$6.08M$5.70M
Operating income-$5.32M-$5.14M-$6.37M-$7.22M-$4.53M
Pretax income-$3.75M-$4.97M-$5.94M-$7.09M-$4.51M
Income tax$23,000$1,000$42,000$51,000$24,000
Net income-$3.77M-$4.97M-$5.98M-$7.14M-$4.53M
EBITDA-$5.24M-$5.05M-$6.29M-$7.14M-$4.20M
EPS (basic)-1.30-2.16-2.84-0.50-0.36
EPS (diluted)-1.30-2.16-2.84-0.50-0.36
Weighted avg. shares (diluted)2.91M2.30M2.10M14.15M12.67M
Balance sheet
Cash & equivalents$1.31M$2.40M$4.17M$9.72M$5.92M
Receivables$785,000$731,000$947,000$722,000$774,000
Inventory$1.71M$1.49M$2.38M$2.06M$2.42M
Current assets$4.02M$4.88M$7.73M$12.80M$9.43M
PP&E, net$78,000$135,000$201,000$213,000$214,000
Intangibles$209,000$228,000$212,000$165,000$170,000
Total assets$6.76M$5.95M$9.25M$14.45M$11.37M
Current liabilities$2.48M$1.74M$2.20M$1.95M$2.01M
Total liabilities$4.13M$1.84M$2.66M$2.73M$3.05M
Shareholders' equity$2.63M$4.11M$6.59M$11.72M$8.32M
Shares outstanding3.20M2.55M2.10M16.82M12.87M
Cash flow statement
Operating cash flow-$3.42M-$3.84M-$5.36M-$5.47M-$479,000
Capital expenditure——$51,000$64,000$57,000
Free cash flow——-$5.41M-$5.54M-$536,000
Investing cash flow-$1,000-$37,000-$115,000-$78,000-$170,000
Financing cash flow$2.33M$2.11M-$81,000$9.39M$2.39M
Depreciation & amortization$77,000$87,000$81,000$84,000$339,000
Stock-based compensation$476,000$460,000$837,000$1.19M$1.26M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.